In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Oren Beske, Amalgamator of Business and Biology at ATUM.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Oren, covering:
How he ended up at Atum with one of the most peculiar job titles in the industry...
The balance (and conflict) of combining a world-class science offering with the economic need of needing to monetise a business
The journey from transactional, smaller deals in the pre-clinical space to powering outsourcing for biotechs
The realities of drug development capability sharing in return for a slice of the profit pie, and its upsides when it comes to a CRO vendor and drug sponsor model

Dr. Oren Beske joined ATUM in 2019 and brings over 20 years of industry experience to the team. After receiving his Ph.D. in Cell Biology at UCSF, he led a biology team at an automated microscopy start-up that was developing solutions for the high throughput, high content screening industry. Having spent over five years there he moved from product development to the services industry and joined Aragen Bioscience. Whilst joining early in the building of the company as the director of laboratory services, he moved up through the VP level and into various C-Suite roles over nearly 11 years and led the company through the acquisition by GVK Bio.
Following a short stint as the president of ImmunoPrecise Antibodies, he most recently served as the founding CEO of Alloy Therapeutics, Inc. serving to set up the company, in-license its seminal discovery platform, and get the first customers on board.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.